Yusuf Lodhi

IDENTIFICATION OF NOVEL MEANS TO OVERCOME RESISTANCE TO VENETOCLAX IN AML

Lector: Dr Michal Smida

Institution: Masaryk University, Faculty of Medicine

Field: Biomedical Sciences

 

About the project

Acute myeloid leukemia (AML) is a disease of poor survival and limited therapy options, primarily relying on chemotherapy. Venetoclax is a novel promising BCL-2 inhibitor, whose efficacy suffers from resistance. Using drug profiling and CRISPR/Cas9 screening, we will identify drugs able to synergize with venetoclax or able to revert venetoclax-resistance. This may reveal unique targets for novel effective targeted therapy to achieve stronger responses compared to single Venetoclax treatment.

 

Why science?

Science is about innovation and discovery and requires a great deal of inquisition. Scientific research is challenging and you must have a great deal of determination to uncover answers to your specific question. I am a naturally curious individual and I am very passionate about my field of research.

 

What do I like most about Brno

I love how Brno is a cosmopolitan student city bringing together scholars and students from all across the world. It has a diverse group of backgrounds and has a rich history in Science which makes me feel as if we are quite literally standing on the shoulders of giants.